Key Takeaways
- Shares of Amylyx surged approximately 21% in pre-market sessions following news that avexitide, its GLP-1 receptor antagonist, achieved all primary and secondary goals in Phase 3 testing
- Study participants experienced 55% fewer instances of severe low blood sugar episodes versus those receiving placebo
- Mizuho Securities upgraded its price objective for AMLX from $24 to $30 while maintaining its Outperform stance
- The drug has secured both FDA Breakthrough Therapy and Orphan Drug designations
- Amylyx is preparing for a New Drug Application and aims for market entry in 2027
Shares of Amylyx Pharmaceuticals climbed approximately 21% during pre-market hours Tuesday following the company’s disclosure that avexitide, its experimental GLP-1 receptor antagonist, delivered successful outcomes in late-stage clinical testing. The stock reached a pre-market value of $26.76, surpassing its previous 52-week peak of $24.60.
Amylyx Pharmaceuticals, Inc., AMLX
The LUCIDITY Phase 3 study was structured as a 16-week, multicenter, randomized, double-blind, placebo-controlled investigation involving 78 participants. The trial evaluated avexitide’s effectiveness in treating post-bariatric hypoglycemiaāa serious condition characterized by dangerously low blood sugar levels following meals, typically emerging years after undergoing weight-loss surgical procedures.
The study successfully achieved its pre-specified primary endpoint established in consultation with regulatory authorities. Participants receiving avexitide experienced a 55% reduction in severe hypoglycemic episodes compared to the placebo cohort.
Additionally, avexitide demonstrated success across all secondary measures. This encompassed data from both patient-administered fingerstick glucose testing and continuous glucose monitoring systems.
The mechanism of action for avexitide differs fundamentally from GLP-1 agonist medications such as Wegovy and Zepbound. Instead of imitating the GLP-1 hormone to reduce blood glucose levels, avexitide inhibits GLP-1 receptors located on pancreatic cells, thereby preventing excessive hormonal signaling following food intake.
Analyst Increases Price Projection
Mizuho Securities lifted its price target for AMLX shares from $24 to $30 prior to the data release, reaffirming its Outperform rating. The firm also designated the stock among its preferred 2026 selections and projected a potential upside of $10 to $15 from previous trading levels contingent on favorable Phase 3 outcomes.
Avexitide has been granted both FDA Breakthrough Therapy Designation and Orphan Drug Designation, regulatory classifications that may expedite the approval timeline.
The company disclosed that preliminary NDA-readiness activities have commenced. Management is targeting a commercial debut in 2027.
Broader Market Environment
The rally occurred against a backdrop of weakness in major indices. The Nasdaq Composite declined 1.2% while the S&P 500 dropped 0.5% during pre-market trading. Biotechnology stocks broadly encountered selling pressure on Tuesday.
Senior leadership at Amylyx conducted a conference call at 8:00 a.m. ET Tuesday to review the study results with investors and analysts.
The organization had initially projected a Q3 2026 timeframe for data disclosure. Tuesday’s announcement represented an acceleration of that schedule.
AMLX’s pre-market valuation of $26.76 represented a substantial advance beyond its former 52-week high of $24.60.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
